Mythili

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Honored to receive the #FASCO designation at this year's #ASCO26 opening ceremony.

Amazing to celebrate alongside so many deserving colleagues @jhaveri_komal @TiansterZhang @cancerassassin1 @KimmieNgMD @thenasheffect @drteplinsky...

[Mythili @Myshastry]

SCRI Oncology Partners Launches New Center for Breast Health and High-Risk Clinic to Advance Care and Empower Patients - SCRI Oncology Partners https://t.co/B6mUU4nGEL

[Farzad Mostashari @Farzad_MD]

1/ After residency at Mass General Hospital, I reported to Atlanta to meet my fellow CDC Epidemic Intelligence Service Officers.

I have never felt so intimidated by my peers

The best and the brightest, they were star clinicians, had served in disaster zones; MD/PhDs and MSF.

[Yakup Ergün @dr_yakupergun]

Genetic mutations/alterations by cancer region👇

[OncoDaily @oncodaily]

📌Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

As Pink October wraps up, it’s time to reflect on the incredible efforts during #BreastCancerAwareness Month. Together, we’ve made strides in raising awareness and support for those affected by this disease.

https://t.co/E7WGLOH0rM

[Mythili @Myshastry]

@ErikaHamilton9 😂

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

What's the implication?

We know PI3 mutant + fast relapsing =poor prognosis that benefits from addition of inavo 1st line in endo/CDK triplet.

Should be profiling these patients up front.

Challenge is tolerability, this can be a rough regimen.

#bcsm

[Mythili @Myshastry]

Dr. Erika Hamilton providing a preview of what’s next with ADCs ⁦@ErikaHamilton9⁩ ⁦@SarahCannonDocs⁩

[Mythili @Myshastry]

@DrSGraff @BrownUniversity Congratulations!!

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Thanks, @OncoAlert

Honored to be including in such great company of people using social media for good!

#bcsm
#oncology

[Mythili @Myshastry]

@ErikaHamilton9 🤞

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Thanks for sharing!

Uniform bias free care is so important and algorthimhs and pathways can help us make sure patients aren't missed for testing.

@JCOOP_ASCO

[Mythili @Myshastry]

@Erikahamilton9 discussing all the new ER-targeting agents in the “ Future of oral SERDs” presentation at SABCS 2023

[Mythili @Myshastry]

@Erikahamilton9 presented exciting data from ph1b study of ER-PROTAC Vepdegestrant+ palbo in ER+/HER2-MBC
CBR 63%
ORR 42%
mPFS 11.1 months

[Sarah Cannon Docs @SarahCannonDocs]

Prevention, detection, unmet needs, and “smart bombs” Dr. @ErikaHamilton9 recaps the latest advancements that will have breast cancer spooked this October and beyond. #BreastCancerAwarenessMonth.
https://t.co/syl7Taw21a

[Mythili @Myshastry]

Dr. Erika Hamilton presenting data from adjuvant monarchE trial @ ASCO 2023
⁦@ErikaHamilton9⁩; @SarahCannonDocs

[Mythili @Myshastry]

Proud to collaborate with @ErikaHamilton9, @tompowles1 and Dr. Sarat Chandarlapaty on this review article
Rise of Antibody-Drug Conjugates: The Present and Future https://t.co/CI3P6eu9BB

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Please join Dr. Chandarlapaty, @tompowles1 & myself at #ASCO23 discussing #ADCs Sun June 4th 4:30-5:45pm in Hall D2.

And if you can't join, luckily @ASCO has the education book manuscripts up already!

Rise of Antibody-Drug Conjugates:Present and Future https://t.co/kPkS8hJcSQ

[Mythili @Myshastry]

@indybobcat78 @ErikaHamilton9 @tompowles1 @ASCO Thank you!

Rise of Antibody-Drug Conjugates: The Present and Future https://t.co/CI3P6eu9BB

[Mythili @Myshastry]

Excellent review by Corti C et al. discussing the new ER targeting agents
https://t.co/czmlkMiEf8